COVID-19 Updates

Best Practices for Long-Term Care Flu Prevention

Helping to Prevent Influenza in Long-Term Care Read what happened when one long-term care facility decided to use an influenza vaccine specifically for residents aged 65+ as the standard of care.

Beginning with the 2015-2016 influenza season, team leaders at a nursing and rehabilitation center in Brooklyn, New York, selected Sanofi Pasteur’s High-Dose influenza vaccine as the single influenza vaccine of choice for all eligible residents 65 years of age and older.

Read this Best Practices newsletter to learn more about their patients and facility experiences. For this upcoming influenza season, Fluzone® High-Dose Quadrivalent will be available.


Fluzone High-Dose Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age or older. IMPORTANT SAFETY INFORMATION Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone High-Dose Quadrivalent is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise. Other adverse reactions may occur.

Before administration, please see full Prescribing Information for Fluzone High-Dose Quadrivalent. CLICK HERE